Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall asserts it will continue its focus on specific areas

Almirall asserts it will continue its focus on specific areas

2nd March 2009

Almirall will maintain its strategy of focusing on specific therapeutic areas, it has asserted.

The comments, from the chairman and chief executive officer of the firm Dr Jorge Gallardo, came after the company released its results for the last financial year.

Revenues of the international pharmaceutical company totalled 136,1 million euros (120,327 pounds), which was an increase of 3.8 per cent compared to 2007.

Net sales also grew by 13.9 per cent over the last year, now standing at 902.8 million euros.

Dr Gallardo explained the results reflected the business’ “fortitude and potential”.

He added that over the next 12 months, Almirall will continue to assess new opportunities with regards to licensing and acquisitions.

The goals behind the objections is to “provide society with the best therapeutic solutions while achieving maximum profitability”, Dr Gallardo concluded.

Based in Barcelona, the pharmaceutical company researches, develops, manufactures and commercialises its own licensed drugs.

It focuses its efforts on treatments for asthma, rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.